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The European Cardiology Section Foundation (ECSF) inaugurated the Cologne
Consensus Conferences (CCC) in 2012. ECSF is the parent organisation of the
European Board for Accreditation in Cardiology (EBAC), one of the specialty
accreditation boards of the European Union of Medical Specialists (UEMS) that
accredits international continuing medical education/continuing professional
development (CME/CPD) in the field of cardiovascular medicine.
CPD accreditation is currently facing a climate of change. The European
associations of medical manufacturers have started a major move regarding
sponsoring and transparency, which is closely related to questions of indepen-
dence and quality of medical information. In parallel, editors of major medical
journals have demonstrated increasing awareness of independence of content and
prevention of scientific fraud. Thus, ECSF decided to create the CCC as an open
forum for discussion of the advancement of accreditation rules, based on the
experience of the past 10 years and taking into account contemporary concepts of
CPD.
This year's CCC focused on the quality of medical information, educational
quality, and the quality of the accreditation process and again offered an
opportunity for discussion among regulators and accreditors, educationalists,
and providers. This text provides a summary of the 2 days’ CCC 2013, which was
held under the patronage of the World Medical Association (WMA), Guidelines
International Network (G-I-N), Accreditation Council for CME (ACCME, USA),
and the Chamber of Physicians Northrhine (DE).
Day 1
Introduction
Professor Heinz Weber, chairman of the ECSF Council, and Marc Jan Eumann,
representing the state government of North Rhine-Westphalia, welcomed
participants to the third meeting of the CCC. The main topic was accreditation
of CPD.
Quality of medical information
Professor Reinhard Griebenow, conference chairman and president of EBAC,
made the first formal presentation. He said that currently accreditation is granted
in relation to the time spent engaging with the educational material and has no
relationship with the quality of the material. He described the continuum of
communication in medicine from randomised controlled trial (RCT) to guideline
and commented on a domino effect where errors early in the continuum sub‐
sequently become accepted as truths. He mentioned evidence that industry-
sponsored research is more likely to report better outcomes and favourable harm
results than non-industry-sponsored research. He made a plea for a hierarchy in
reporting trial results that must include mortality and morbidity and also that
Correspondence: Robin Stevenson, editor of
JECME
History
Published online: 27 January 2014
          Journal of
European CME
The Open-Access Journal on CME-CPD Practice
Journal of European CME (JECME) 2014. # 2014 Robin Stevenson. This is an Open Access article distributed under the terms of the Creative Commons CC-BY 4.0 License (http://creativecommons.
org/licenses/by/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for any purpose, even
commercially, provided the original work is properly cited and states its license.
1
Citation: Journal of European CME 2014, 3: 23751 - http://dx.doi.org/10.3402/jecme.v3.23751negative studies should always be published. The language
of reports should discriminate among causal relationships
and associations. Conclusions must accurately reflect the
data and must not include biased statements not justified
by study findings.
In questions after the presentation, doubt was ex-
pressed that, in the present European system, guidelines are
not always accredited. A comment was made that it may be
difficult to have negative studies accepted for publication.
Professor Gerd Gigerenzer from the Max Planck Insti‐
tute for Human Development, Berlin, raised the ques‐
tion ‘What does a 30% chance that it will rain mean?’.
Meteorologists, like doctors, communicate probability
badly. Doctors do not understand statistical evidence,
and patients similarly do not understand probabilities.
He cited a study where 98% of German women over‐
estimated the benefits of mammography screening and
99% of UK men overestimated the benefits of prostate-
specific antigen (PSA) estimation. The most realistic
European nation was Russia, where the people are exposed
to less information from doctors.
He then described the ‘seven sins that contribute to
patients’ health illiteracy’.
1. Biased research funding, not directed to areas that
are relevant to patient care (e.g. to development of
checklists for procedures or to helping doctors
become more statistically literate). It is more
useful to investigate ways of improving health
literacy in patients than to develop new cancer
drugs.
2. Biased reporting in journals with lack of transpar-
ency and specifically mismatched framing using
relative risks to report benefits and absolute risks
to report harms. Journal editors and reviewers
need education in transparent and honest pre-
sentation of data.
3. Biased reporting in health pamphlets (e.g. lead-
time bias due to screening with no change in real
mortality and overdiagnosis, where low risk can-
cers detected by screening are included with
progressive cancers). This problem can be solved
by generating ‘fact boxes’ in which data are pre‐
sented in a transparent way.Sometimes it may help
to show risks using icons rather than numbers.
4. Biased reporting in the media—journalists are
statistically illiterate and should receive statistics
training. There should also be media watchdogs to
refute misleading claims.
5. Commercial conflicts of interest (COI)—problems
with fee-for-service systems and CME sponsored
by the pharmaceutical industry.
6. Defensive medicine—in a US study, 93% of
doctors admitted practising defensive medicine
because of litigation risk. In Switzerland, the
hysterectomy rate in the general population is
16%, but it is only 10% in female doctors and
doctors’ wives. Pressure should be brought to bear
on governments to amend legislation that favours
the development of defensive medicine.
7. Doctors’ lack of understanding of health statistics
—American doctors do not understand the dif-
ference between 5-year survival statistics in cancer
screening patients and mortality rates. There are
similar findings in Germany—almost no German
physicians understand lead time bias and overdia‐
gnosis in screening programmes. Medical schools
and CME should undertake to improve doctors’
statistical literacy.
He concluded by summarising the ways in which the
profession can try to deal with the seven sins.
Dr Regine Potthast, Institute for Quality and Efficiency
in Health Care, Cologne, discussed the contribution that
can be made by clinical investigators. She said that,
from accredited CME, a physician wants a synthesis of
all relevant studies of appropriate quality that will help to
guard against wrong decisions and false expectations.
Drug trials must not only define risk benefit ratios for
a new drug but also show that it is better than existing
treatments. Therefore, trials must include a standard treat‐
ment as a comparator, and outcomes must be measured
in terms of relevance to patient well-being. It is also im‐
portant that studies are designed with appropriate control
arms. There must be only one variable between control
and trial arms and the trial drug must be compared to
standard practice rather than to placebo.
Studies with positive results are published more quickly
than studies with negative results, which may lead to a false
judgment on the quality of a new drug. Indeed, negative
studies may never be published. A further problem is the
reduction in the amount of the study data when the study is
published in a journal in comparison to the data actually
obtained in the study. She concluded by emphasising that
studies should not only seek to satisfy regulatory autho-
rities but also define the new drug in relation to everyday
practice; second, clinical evidence should be transparent
and complete and all trial data should be publicly available.
Questions highlighted the difficulty in publishing all
trial data and pleas were made that governments and
journal editors should be persuaded to act in this area.
However, journals are concerned with maintaining or
improving their impact factors, and positive trials are
more likely to be cited than negative trials. In addition,
editors may be reluctant to publish negative studies that
will not change clinical practice.
Dr Norbert Steinkamp, bioethicist, Institute for the
Quality of Healthcare, Radboud University, Nijmegen,
discussed ethical aspects of recommendations for clinical
practice. He quoted Schofferman as showing that although
physicians think of themselves as being impervious to
marketing, the evidence indicates that they are indeed
vulnerable to it. He then quoted Pellegrino, who said that
a profession was distinguished from other occupations
by the elimination of self-interest. Physicians should be
Copyright # 2014 Robin Stevenson
2 Robin Stevensontrusted to use their skills not for their own benefit. Doctors
should be trusted to help patients, to preserve confidenti-
ality, and to provide true information to patients.
He contrasted morality, which encapsulates man's
convictions about right and wrong in human behaviour,
with ethics, which involves critical reflection on morals,
principles, and values. He described seven criteria that
must be followed in clinical research: (1) value, (2)
scientific validity, (3) fair subject selection, (4) favourable
risk-benefit ratio, (5) independent review, (6) informed
consent, and (7) respect for enrolled subjects. He then
described six criteria for ethical clinical practice: (1)
principles of beneficence and non-maleficence, (2) respect
for the patient's autonomy and integrity, (3) respect for the
doctor's autonomy and integrity, (4) shared decision-
making and patient empowerment, (5) compassionate
professional care, and (6) justice issues.
Recommendation goals for clinical practice include
reduction in complexity of information generated by re‐
search, education of practising physicians, translation of
information into the clinical context, and transfer of
research data into a narrative of patient care. He finished
by making a plea for medicine to be considered as a
moral community for the benefit of patients and thereby
allowing trust to be generated.
Discussion highlighted the dilemma between sympto-
matic relief and aggressive treatment that was unlikely to
be successful in terminal illness. Inadequately powered stu‐
dies were also mentioned as being unfair to patients and
therefore unethical. Accreditation has a responsibility to con‐
sider these and similar issues when reviewing applications.
Dr Juan Garcia Burgos, European Medicines Agency,
London, spoke on the role of regulators in providing
information on healthcare. The EMA provides the mem-
ber states and European institutions with scientific advice
on the evaluation of the quality, safety, and efficacy of
medicines. More specifically, the agency is responsible
for (1) the evaluation of marketing and authorisation of
applications submitted by pharmaceutical companies, (2)
coordination of pharmacovigilance at the European level,
(3) provision of scientific advice on the development of
medicines, (4) evaluation of applications of orphan desig‐
nation in EU for rare diseases, (5) evaluation of paediatric
investigation plans, and (6), since 2005, provision to
patients and health professionals of good quality, evi-
dence-based, independent information on the safe use of
medicines. The EMA is not responsible for controlling
advertising or pricing and does not advise on clinical use.
It is primarily concerned with patient safety.
There are two systems for marketing approval in
Europe. A centralised procedure is performed by the
EMA, but there is also a decentralised procedure that
provides national licenses. Both systems allow harmonised
scientific opinions and information to doctors and patients.
However, the centralised system just involves one applica-
tion and evaluation, and there is only one authorisation
for all the EU countries and one version of product
information. This system is preferable to the decentralised,
national system.
The following medicines must be evaluated at the EMA:
(1) treatments for rare diseases; (2) drugs for human im‐
munodeficiency virus (HIV), cancer, diabetes, and neuro-
degenerative diseases; (3) drugs for autoimmune and viral
diseases; (4) all biotech products; (5) gene therapy; and
(6) monoclonal antibodies and most other innovative
products.
The EMA provides information mainly via its website.
The information changes during the different stages of
drug development and includes safety data for all medi-
cines authorised in the EU. He then described the life cycle
of a drug in his system:
Pre-authorisation: applicable to orphan drugs and
paediatrics. In addition, clinical trials are documented in
the EU Clinical Trials Register website linked to the EMA
website, with information on trial design, sponsorship,
therapeutic area, and status of the trial.
Authorisation: when a drug is authorised, the European
public assessment report (EPAR) summary is published
online with all details of the new drug in all EU languages
along with product information that is designed for the
medical profession and for patients.
Post-authorisation: additional information on new
therapeutic indications or new contraindications is added
to the website.
Communication about safety referrals is performed
by the Pharmacovigilance Risk Assessment Committee
(PRAC), which meets monthly. Its recommendations are
syndicated to the press, patients, and to healthcare pro‐
fessionals. The EMA also publishes the monthly Human
Medicines Highlights newsletter, which includes details of
new drugs and safety issues that have been dealt with
during the previous month.
A further database of the EMA provides information on
adverse drug reactions for medicines authorised in the
EU—but so far only for medicines approved via the
centralised procedure. The reports are constantly updated.
He concluded by saying that the EMA provides up-to-
date, evidence-based information on the rational and
safe use of medicines. Presenters of CME/CPD should
be aware of all pertinent EMA data on relevant drugs that
should be transmitted to healthcare professionals.
During questions, it was admitted that a major dif‐
ficulty in transmitting information throughout Europe is
related to language. It was suggested that use of icons
and fact boxes might be helpful. Criticism against the
EMA was expressed because it had not alerted Europe to
some recent instances where drug companies had with-
held important information about new drugs. Dr Burgos
pointed out that the EMA had no power to force pharma‐
ceutical companies to release data, and this required
involvement by national governments.
Dr Georg Röggla, assistant editor of the British Medical
Journal (BMJ), discussed what editors can do to improve
the quality of medical information. He quoted Douglas
Altman who wrote in 1994 about the scandal of poor
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better research, and research done for the right reasons.
He suggested that researchers make so many errors
because research is often carried out for career advance-
ment by doctors who are ill-equipped to perform the
research and nobody stops them. This occurs when
research ethics committees do not consider the scientific
aspects of proposed studies. Different issues are addressed
by journalists. He quoted Ben Goldacre who writes for the
British Guardian newspaper and who campaigns against
pharmaceutical companies who do not publish all the
results of clinical trials. However, journalists and politi-
cians also mislead the public.
He then described the mission statement of the BMJ
(a publication that is downloaded by 1.67 million users
each month). Its impact factor is 17.215 and readers’
comments on articles are published online within 48
hours. The BMJ operates an open peer review system and
reviewers sign their reports. The journal gives priority to
original studies that can improve medical practice and has
a rejection rate of around 93%. It does not just publish
positive studies but will publish negative ones, if impor-
tant. However, it does not accept laboratory based or
animal research or studies on volunteers rather than on
patients. These are considered too preliminary for BMJ
readers. It does not publish prevalence or cost of illness
studies, open loop audits without intervention and re-
audit, or placebo-controlled drug or device trials. The
research message must be important, clear, and original.
The study design must be appropriate for the question
being asked. There must be adequate control groups.
Randomised control trials must have adequate statistical
power, validated research instruments, minimal deviations
from the trial protocol, and proper analysis of harms.
The validity of studies requires consideration of inclu-
sion and exclusion criteria, whether study participants
are representative of most patients with the disease, and
whether the intervention is compared against best current
treatment rather than against placebo. The study's re-
search question should still be relevant and not out-of-
date. The BMJ looks for appropriate checklists for RCTs,
metanalyses, and observational studies. Studies also need a
study protocol and ethics committee approval.
Dr Amir Qaseem, chairman of the Guidelines Interna-
tional Network, Berlin, and director of clinical policy of
the American College of Physicians, spoke on the role
of medical scientific societies in relation to the quality of
medical information. He noted how fast medical literature
is expanding. RCTs in MEDLINE have increased from
5,000 annually in 1978–1985 to 25,000 annually in 1994–
2001. There are 15 million citations on MEDLINE with
10,000–20,000 added every week. Physicians, patients,
legislators, and insurance companies need to participate
in available medical education, which is now a multibillion
dollar industry. Commercial support for CME now op‐
erates at US$1.2 billion annually with profit margins for
medical societies at 46.3%. Everything is a business.
Medical specialty societies have an important role in
defining and advancing healthcare standards. Members
and patients rely on societies to be authoritative and in‐
dependent, and public confidence in the objectivity of
these societies is critical. Education is delivered at con-
ferences, in courses, with the use of practice guidelines,
through the definition of ethical norms, and by publication
in journals. However, there are concerns about the quality
of content, lack of uniform standards, COI, poor formula-
tion of key questions, lack of a standard reporting system,
and failure to address all outcomes.
The societies must play a part in minimising COI,
encouraging full disclosure of financial and non-financial
conflicts by everyone involved in educational programmes,
and in describing how COI are recorded and resolved.
The societies must be independent of influence by the
pharmaceutical industry while admitting that some of
their funding comes from the industry. COI requirements
must be known by members. All financial support must be
disclosed, and the role of sponsoring organisations must
be clear and transparent. All education should be evi-
dence-based with quantification of benefits, harms, and
costs. The widely accepted standards for guideline pre-
paration should be followed.
Dr Murray Kopelow, chief executive officer of the
Accreditation Council for CME (ACCME), Chicago, spoke
on the role of accreditors in relation to the quality of
medical information. In contrast to the criteria for accep‐
tance of papers for journals, accredited CME does not
need to be new, but it must be true and important to the
learner. There are three main elements in the ACCME
system, and the first is practice-based content relevant to
professional practice gaps. This is not restricted to clinical
practice gaps but includes educational, research, and
administrative practice. The second element is indepen-
dent accredited CME, which has been required in the
United States since 1985. Commercial interests can pay
for CME but cannot control it. The provider of CME
separates promotion from education and actively pro-
motes improved healthcare. The third element comprises
other valued attributes. The CME must be designed to
change competence, performance, and outcomes; the
educational formats must be appropriate for the activity
(e.g. didactic or interactive depending on the goal of the
activity).
In a highly regulated region such as the United States,
accreditors must not allow a regulatory vacuum but must
determine the correct amount of regulation to encourage
providers to be active. Experience shows that the right
amount of regulation does lead to increased educational
activity. Providers may not receive guidance from a
commercial interest on the content of an activity or on
who should deliver the content. This is not just an ethical
rule, it is enforceable by law. When industry infringes
upon this law, people go to jail. ACCME's main function is
to prevent bias, not to ensure truth in education. The
providers are responsible for validating the clinical content
of their activities, and all recommendations must be based
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that is quoted must conform to accepted experimental
standards and not be based on limited anecdotal informa-
tion. Providers who advocate unscientific methods of
diagnosis or treatment are not eligible for accreditation
(e.g. advocates of alternative medicine). In addition to
these primary measures for the prevention of bias,
secondary measures require documentation of personal
COI resolution and full disclosure.
During questions, Dr Kopelow was asked about re-
quests for proposals (RFP). He said commercial interests
were entitled to identify practice gaps but could not
design activities to deal with them. He was asked to
describe the range of continuing education providers in
the United States. He replied that they were represented
by the participants of the conference: commercial medi‐
cal communication agencies, medical societies, medical
schools, hospitals, government agencies, and state medical
societies but not commercial interests that provide drugs
or devices. There was also a suggestion that hybrid
accreditation systems might develop that include both
activity and provider accreditation.
Holger Diener, from the Association of Voluntary Self-
Regulation for the Pharmaceutical Industry (FSA), Berlin,
spoke about the role of industry in relation to the quality
of medical information. His organisation is composed of
62 pharmaceutical companies with 25 dependent compa-
nies. He discussed the codes of conduct that define the
relationship between the industry and healthcare profes-
sionals. Penalties for violations of the codes may be as
much as t400,000.
Information about medicines is complex and continu-
ally expanding. Therefore, there must be close cooperation
between drug companies and the medical community to
provide patients with the best available treatment. This
exchange of information must follow strict rules to avoid
the impression of bias. It must be accurate, balanced,
objective, and complete. It must encourage sensible use of
medicines. Nevertheless, there is a perception in some
places that the drug industry deliberately misleads doctors
and that doctors should therefore avoid all exposure to
information from the industry. He then quoted Ben
Goldacre, who has written that almost everybody has
COI, but that does not mean that it influences behaviour.
The most common approach to COI is that it should be
declared rather than outlawed, otherwise all communica-
tion between the industry and doctors will stop. Complete
transparency is the key. All sponsorship must be fully
disclosed.
He then referred to the Sunshine Act in the
United States, which was followed earlier this year in
Europe by the European Federation of Pharmaceutical
Industries and Associations (EFPIA) disclosure code of
transfers of value from pharmaceutical companies to
healthcare professionals. The EFPIA categories of disclo-
sure include funding for research and development,
donations and grants to healthcare organisations, con-
tributions to costs of events, and consultancy fees.
Day 2
Educational quality in CME/CPD
Professor Janet Grant, director of the Centre for Medical
Education in Context and professor emerita of the Open
University, spoke on doctors’ changing knowledge, their
community of practice, and CPD. CPD involves patient
safety and ethics, cost-effectiveness, professional regula-
tion and development, personal and professional satisfac-
tion, and international standards. Contextual factors in
CPD may be economic, personal, social, professional,
political, academic, local, and national. It should be based
on personal needs, service requirements, and professional
needs.
Medical education comprises knowledge, skill, practice,
and professional context of which the latter becomes
increasingly important. It is a play of three acts, first
medical school, then post-graduate training, and finally,
CPD. Abstract learning is replaced by theory in practice,
which itself becomes the source of learning needs and the
focus of development.
Individuality characterises a profession. Experience is
different for all professionals and information in memory
is organised in different ways. Doctors use increasing
knowledge in diagnosis until they become consultants,
after which they need to use less knowledge because
experience partially replaces the need for book learning.
There is little uniformity in the ways doctors think about
clinical problems, particularly as they become more
senior. The variability relates to memory structures that
are individual, tailored through practice, and that become
better organised with experience.
Doctors develop individual approaches to practice,
with individual learning needs. There is no best method
of learning, and linking CPD to known needs may not
prepare for the future nor promote an individual's de‐
velopment. Doctors are aware of how best they learn and
know what they need to learn. Occasionally, a new area
will require teaching, but in general, CPD will arise from
the practice and judgment of doctors. There should not be
a pre-specified curriculum.
CPD is a simple four-step process: (1) WHAT will be
learned, (2) HOW will it be learned, (3) LEARN, (4) USE
the learning and show effects. After identifying what to
learn, the method of learning varies from reflection to peer
review and quality assurance processes, and the effect
ensures that the learning derives from a relevant need.
How to learn requires a personal development plan with
the effect that a rational and transparent record is created.
The learning step is carried out in any way that is deemed
appropriate by the learner such that the process is
personally effective. The use of the learning and showing
its effects requires dissemination to others and incorpora-
tion into practice with the effect that the learning is
carried back to the workplace.
In some respects, collecting CPD credits has little
benefit. There is no real underlying rationale, no relation-
ship to need, no evidence of effect on practice, and doctors
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the collection of credits ignores context and community,
which are essential for good CPD, and so we have to try to
do better.
Professor Martin Fischer, chair for medical education,
Ludwig Maximilian University, Munich, spoke about how
CME course directors and presenters meet the needs of
the participants. First, he considered the effectiveness
of CME formats. Interactive methods are very effective,
especially those related to daily practice, outreach activ-
ities, and skills with active repetition; less effective are
audit, unmoderated quality groups, and opinion leaders;
least effective are traditional lectures and print media. He
presented a US pyramid figure indicating retention rates,
with the lecture at the narrow peak associated with 5%
retention, followed toward the base of the pyramid by
reading, audiovisual, demonstration, discussion groups,
practice by doing, and teaching others at the large pyramid
base associated with 80% retention. He described a
curriculum development cycle with seven steps: general
needs assessment, needs of targeted learners, learning
goals, teaching methods and strategies, implementation,
evaluation and feedback, and maintenance with sustain-
ability. The curriculum can thus be subdivided into what is
declared (what is assumed the students are learning), what
is taught (the presentation), what is learned (actual
learning), and what is examined (what students are asked
after learning).
Competence is difficult to define and to measure.
Evidence is needed but what should be the measuring
currency is improved participant outcomes! He contrasted
instruction versus construction; first is information pre-
sentation, where learning materials stimulate sensory
memory; next is information organisation, using short-
term memory; that is followed by information integration
in long-term memory augmented by prior knowledge.
He supported formative assessment before and at the
beginning of a CME event carried out by questionnaires,
self-assessment, and external assessment. One study
suggested that knowledge retention was better served by
retesting learners rather than by repeating the learning
activity, although the effect was only evident shortly after
the activity. Progress along the continuum of competence
is aided by combining teaching methods—lectures, virtual
patients, standardised patients, patient simulators, and
ending up with real patients.
There is no learning without feedback. Summative
information is not helpful, and feedback is best when
formative and knowledge of correct results is given along
with specific actions for gap reduction. He described the
“sandwich” approach with the separate phases of gaining
attention, processing information, storing information,
and applying information. This approach contributes to
higher learning levels, a positive learning climate with
retention of information, and to improved self-study
behavior.
Outcome measurement occurs at four levels: Reaction
—did the learners like the training? Learning—what was
learned? Behaviour—what was applied at the workplace?
Results—what was the impact? The evaluation framework
comprises process, outcome, and transfer—hopefully result‐
ing in added value, cost reduction, and improved cost-
benefit ratios.
He finished by emphasising key points: (1) assess needs
before and during the event, (2) test participants, (3) let
participants elaborate and collaborate, (4) give formative
feedback, (5) try the sandwich approach and combine
methods, and (6) teachers should take risks to activate
their learners.
Dr Martin Balzan, president of the Pneumology Section
and Board of UEMS and secretary of the European Board
for Accreditation in Pneumology, spoke about the theory
and practice of e-CME. In the business world, e-learning
marketing claims it has lower costs, faster delivery, more
effective learning, lower environmental impact, and that it
is more convenient. There is evidence that blending live
events with e-learning is more effective than e-learning
alone. In medicine, user convenience of e-learning is clear.
Doctors can choose their preferred time and place for
learning. Protected time is not required, and it is female
friendly because women have family responsibilities that
make demands on the organisation of their time.
A US meta-analysis of online learning showed that
students engaged in online learning performed somewhat
better than with face-to-face instruction. Further improve-
ment occurred when the two modalities were blended
together. A UK study of medical trainees concluded that
an e-learning course in evidence-based medicine was as
effective in improving knowledge as a standard lecture
course and was potentially cost-effective. A recent Learn‐
ing Insights report, noted that there is less need to assess
learning; what matters is how well staff do the job. Passing
a test does not mean that behaviour will be changed in the
workplace. Dr. Balzan referred to the European Respira-
tory Society's e-learning programme, which includes case
reports, CME tests, procedure videos, and CME online
modules. He also mentioned e-learning clinical scenarios
that are designed to improve decision-making but are still
in their infancy in medicine.
Dr. Balzan went on to describe his own experience in
Malta where he has developed a Moodle online e-learning
management system that is sharable content object re‐
ference model (SCORM) compliant. It includes weekly
presentations by consultants during clinical meetings and
is followed by quizzes prepared from material covered in
the lectures. Articulate™ was the software used. He has
also observed the usage pattern of trainees and assessed
feedback on usefulness. He found that the trainees left
everything until the last minute, especially the males.
Much of the learning activity took place at the weekends
and after working hours, again more noticeably with the
male trainees. Males spent more time on the modules than
did the females. It was generally felt that the system was a
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good when the system was incorporated into the curricu-
lum. He was concerned that males spent more time on the
modules than females and wanted to assess if the learners
were actually in front of the screens during the supposed
learning. He found that many trainees learned to skim
through the slides, and that often they were not in front of
the screens all the time. He concluded that the systems
must be designed so as to ensure proper compliance.
During discussion, it was suggested that it is no longer
acceptable to expect trainees to study during non-working
hours. Another possibility mentioned was that e-CME
might take place using social media.
Martina Siedler, head of e-publishing, Springer Medizin
Journals, Heidelberg, spoke about the concept and rules
of procedure for CME publishing. Springer Medizin has
more than 65 scientific journals and magazines and pub‐
lishes 55 journals with CME. In 2012, Springer launched
e-Akademie, a new learning platform. The company
focuses on CME quality in scientific knowledge, medical
practice, and procedures. Each journal has a ‘CME’
editorial board that invites experts to submit CME papers.
Articles and multiple choice questions (MCQs) are peer-
reviewed by appropriate specialists. Evaluation and a help
desk are available for authors. The majority of CME
participants are aged 40–70 years. There are almost twice
as many males as females, and most participating physi-
cians are in private practice. Peak participation is between
5 pm and 7 pm, and Sunday is the most popular day.
Springer's aim is to continuously improve its quality
control at all levels.
During discussion, it was noted that impact factor
was related primarily to research communication; at
present, journals are deeply engaged in CME, which is
not encompassed by impact factor consideration. It was
suggested that, in the future, journals should be less
concerned with the traditional concept of the impact
factor.
Quality of the accreditation process
Dr Murray Kopelow, chief executive officer of the Accre‐
ditation Council for CME, Chicago, spoke on sources of
accreditation variability. In the United States, there are
approximately 25,000,000 individual registrants annually
in CME, which is composed of nearly 150,000 activities
with almost a million hours of instruction. There are some
700 nationally accredited providers and nearly 1,500
providers accredited by state medical societies. ACCME
rules are set down in ‘Updated Accreditation Criteria’ and
‘Standards for Commercial Support’. The endpoint is the
provision of optimal patient care.
The ACCME process starts with a provider self-study,
which is then reviewed by the ACCME. Activity files are
reviewed by a surveyor and these two sources of informa-
tion are integrated. There may then be new information
after the provider is interviewed. The Accreditation Review
Committee makes a recommendation, which is then
considered by the ACCME board. The board makes the
decision on accreditation status. Each year, there are 150
accreditation reviews and 90 progress reports from provi-
ders who have previously been non-compliant. The AC-
CME process must be reproducible and valid. Internal
controls are necessary to maintain consistency. Layered
strategies are used to maximise validity and reliability:
(1)afoundationofethicsandvalues,(2)publishedrulesand
processes, and (3) rule-based outcomes. As an organisation
matures,volunteersarecomplementedbyprofessionalstaff
necessary to maintain fair and consistent treatment of
providers. There must be one set of requirements for
all providers with explanations and interpretations pub-
lished on the ACCME website. Staff are designated to be
responsible for internal and external communication, and
there must be common understanding among all staff
members about the rules. Internal controls require stan-
dardisation of all aspects of the process, its interpretation,
and the outcomes. As the system has become more
established, the degree of non-compliance has decreased.
The reliability of accreditation decisions is supported by
comparison between ACCME decisions and those of state
medical societies that have been found to be similar. It is
important that the system does not overburden providers
with bureaucracy so that providers are able to concentrate
on education rather than accreditation.
Professor Lampros Michalis, professor of cardiology,
Ioannina, Greece, spoke about professional autonomy
in CME/CPD. Medical professionalism includes mainte-
nance of competence, adherence to ethical codes of
conduct, exercise of discretionary judgment, and dedica-
tion to self-regulation. This allows medicine to enter into a
contract with society granting it a monopoly over the use
of its knowledge base, the right to autonomy in practice,
and the privilege of self-regulation.
Professional autonomy is the freedom to exercise our
own judgment in the treatment of our patients. It is
important because it is an essential component of high-
quality medical care. Areas of self-regulation include
quality of care provided to patients, cost consciousness,
conduct of physicians, and newly developing problems.
However, autonomy is being re-evaluated by society
because of recent high profile medico-legal cases, a public
perception that doctors protect their own, a suspicion that
research may be biased by industry, and because of the
technological revolution that has allowed access to pre-
viously restricted medical information. There is now
discussion on whether a new social contract between
doctors and society is needed.
One of the justifications for autonomy is doctors’
engagement in CME/CPD in order to apply the latest
knowledge for the promotion of health and to ensure
ethical standards governing the thoughts and behaviour of
doctors. CME/CPD should be provided by the profession
through medical schools, hospitals, and medical societies.
New knowledge and skills are based on new drugs,
instruments, and diagnostic tools—all of which are pro-
duced by industry, whereas management strategies are
developed by doctors. This interaction between doctors
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also leads to COI that can affect the delivery of care to
patients and that may damage the reputation of the
profession.
COI may be present in the education of doctors, in
relation to their institutions, and may be associated with
research activities. The latter must be conducted for the
advancement of medical science, and all relevant relation-
ships should be disclosed. Trials should be accessible
through public registries. Financial arrangements must be
fully disclosed. The research should be owned by the
investigator and not the sponsor, and the investigator
should have the right to publish negative results and to
release relevant information at any time.
In industry-sponsored research, the doctor must com-
ply with the law and the Helsinki Declaration and must
apply his clinical judgment in the performance of the
research. Ideally, research should be supported financially
by more than one company. Identifiable information
about research patients should be confidential and not
given to a sponsor. When results are published, sponsor
details must be provided. Results may not be suppressed
by commercial interests. Doctors’ financial compensation
should be unrelated to results. Investigating doctors must
not allow themselves to be subjected to external pressure
in the publication of their results.
In industry-sponsored CME, hospitality should not
exceed what is locally customary and generally acceptable.
Doctors should not receive direct payment for travel and
subsistence at conferences. Accompanying persons at
international meetings should not be helped financially
by sponsoring companies. Presentations should not be
influenced by sponsors, and all support must be publicly
disclosed. Speakers must fully disclose their own financial
affiliations. Sponsors may not influence programme de-
sign, choice of speakers, or publication of presentations.
Financial support is given as a contribution to general—
rather than specific—costs of the event.
In order to maintain autonomy in CME/CPD, the
medical profession should have independent bodies that
will create regulations adequate to reassure the public.
These bodies will negotiate with government agencies
involved in introducing new laws that may impact the
medical profession. Dr. Michalis concluded by saying that,
if these measures are taken, professional autonomy in
CME/CPD will remain feasible.
Dr. Ferdinand Hundt, head of clinical research and
regulatory affairs, Berlin University for Professional Stu-
dies, and Professor Heinz Weber, chairman of the ECSF
Council, debated whether industry representatives should
be allowed to present in accredited CME/CPD activities.
Dr Hundt argued in favour, from a German perspective.
He quoted from German law that ‘Arts and sciences,
research, and teaching shall be free’, but that the freedom
of teaching shall not release any person from allegiance to
the constitution. Doctors are influenced by their employ-
ment as general practitioners, by their hospitals, health
insurance companies, government agencies, political par-
ties, trade unions, industry, medical professional associa-
tions, and by scientific societies. However, the CME code
requires that educational content must be free from
economic interests, and that the COI of organisers and
the scientific head and speakers must be disclosed. Only a
medical doctor can be nominated as the scientific head,
and he or she must be present during the meeting.
Doctors engaged in CME are required to be indepen-
dent of ideological and commercial interests. Dr. Hundt
felt that all doctors had such interests but had to find ways
to control them. Speakers must have multi-year medical
experience that excludes presentation by non-medical
experts. Presentations should be interactive, and informa-
tive summaries in the form of handouts should be pro‐
vided. Sponsors may not influence the form and content
of CME. Connections between speakers and industry must
be disclosed. Product advertising on invitations and pro‐
grammes of single-sponsor CME is not permitted. All
CME must communicate a balanced overview. Accom-
panying commercial programmes may not take place
along with the accredited CME. Dr. Hundt quoted an
updated Cochrane review that concluded that interactive
education was more effective than didactic presentation
and that a mixture of both was most effective.
By implication, although not explicitly stated, Dr Hundt
appeared to be supporting industry involvement in CME/
CPD if German law and codes of conduct were not
contravened.
Professor Weber argued against the proposal for
industry involvement in the presentation of CME. He
began by saying that doctors have an ethical duty to
engage in CME/CPD. In Europe, the cost of CME is not
adequately supported by governments and employers.
When there is industry support of CME, communication
may lack objectivity. Patients now expect more from
contact with a doctor. They want information, personal
investigation, drug prescriptions, and referral to appro-
priate specialists. The patient wants to understand his or
her disease and wants a realistic prognosis. They may also
want to know who is the ‘best doctor’ for their case.
Doctors are under conflicting pressures. On the one hand,
industry attempt to provide incentives for doctors to
prescribe specific drugs; on the other hand, the healthcare
system wants doctors to be economical in prescribing
medications.
Industry bias is manifested by companies that finance
studies with associated commercial interests. Study de-
signs may be biased. Companies now promote diseases
treatable by their drugs, rather than promoting their
drugs for established diseases. Scientific presentations may
be scrutinised by companies. There may be publication
bias in which negative studies are not published. Academic
bias is also related to conflicts of interest, publication bias,
direct payment from companies, lack of balance and
objectivity, and even scientific fraud (with selective
statistical analysis).
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of a medical company can serve as a member of a pro‐
gramme committee and from EACCME that the industry
partner will not interfere with the educational programme.
Dr Weber endorsed these statements and concluded that
his answer to the proposal that industry may be directly
represented in CME/CPD activities is ‘NO’. His model for
cooperating with industry requires an academic provider
for educational events; this provider may be a university or
other academic institution to which industry will make
an unrestricted grant. The academic provider will appoint
an academic director who will be responsible for the
program. The academic provider may have to engage the
services of CME companies for operative support for
which the academic provider will pay. There should be no
money flow from industry to the CME companies or to
the academic director and speakers.
At the final roundtable discussion, there was agreement
that the meeting had been valuable, interesting, and
informative. Professor Griebenow was thanked for orga-
nising it, and participants looked forward to next year's
meeting, which will concentrate on management of
COI (to be held Sept. 12th/13th, 2014). The presentations
of the CCC 2013 will also be available on the ECSF
homepage (www.e-cs-f.org).
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